Condition: Ischemic Stroke · Sponsor: Translational Sciences, Inc.
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
This description comes directly from the study's public registry record.
Rebeca Aragon Garcia, BS, CCRC · 9736688644 · aragonra@ucmail.uc.edu
Pam Plummer, MSN,RN, CCRC · 5138852437 · plummepa@ucmail.uc.edu
Always discuss trial participation with your own doctor first.
| University of Alabama Hospital | Birmingham, Alabama, United States | Recruiting |
| Banner University Medical Center | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic Phoenix | Phoenix, Arizona, United States | Withdrawn |
| Banner University Medical Center - Tucson | Tucson, Arizona, United States | Not Yet Recruiting |
| UCSD Health La Jolla | La Jolla, California, United States | Recruiting |
| Kaiser Permanente Los Angeles | Los Angeles, California, United States | Recruiting |
| Sutter Medical Center | Sacramento, California, United States | Withdrawn |
| UCSD Medical Center- Hillcrest Hospital | San Diego, California, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Christiana Hospital | Newark, Delaware, United States | Recruiting |
| UF Health Shands Hospital | Gainesville, Florida, United States | Terminated |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05948566